Literature DB >> 18802209

Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council.

Adrian Covic, Jorge Cannata-Andia, Giovanni Cancarini, Rosanna Coppo, João M Frazão, David Goldsmith, Pierre Ronco, Goce B Spasovski, Peter Stenvinkel, Cengiz Utas, Andrzej Wiecek, Carmine Zoccali, Gerard London.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18802209     DOI： 10.1093/ndt/gfn519

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  14 in total

1.  Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects.

Authors:  Bo Zhou; Birong Lin; Jing Li; Weizhu Qian; Sheng Hou; Dapeng Zhang; Geng Kou; Bohua Li; Hao Wang; Yongchuan Chen; Yajun Guo
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

2.  Biosimilars: Implications for health-system pharmacists.

Authors:  Steven D Lucio; James G Stevenson; James M Hoffman
Journal:  Am J Health Syst Pharm       Date:  2013-11-15       Impact factor: 2.637

3.  Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.

Authors:  Giovanni Barosi; Alberto Bosi; Maria P Abbracchio; Romano Danesi; Armando Genazzani; Paolo Corradini; Fabrizio Pane; Sante Tura
Journal:  Haematologica       Date:  2011-07       Impact factor: 9.941

4.  Interchangeability, immunogenicity and biosimilars.

Authors:  Hans C Ebbers; Stacy A Crow; Arnold G Vulto; Huub Schellekens
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

5.  A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.

Authors:  Franziska Hörbrand; Peter Bramlage; Johann Fischaleck; Joerg Hasford; Reinhard Brunkhorst
Journal:  Eur J Clin Pharmacol       Date:  2012-10-02       Impact factor: 2.953

Review 6.  Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.

Authors:  Bradley A Warady; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2013-09-05       Impact factor: 3.714

7.  Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden.

Authors:  Carl-Erik Flodmark; Katarina Lilja; Heike Woehling; Kajsa Järvholm
Journal:  Biol Ther       Date:  2013-05-28

Review 8.  Anemia in chronic kidney disease.

Authors:  Meredith A Atkinson; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2017-04-15       Impact factor: 3.714

Review 9.  State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.

Authors:  Adrian Covic; Ivo Abraham
Journal:  Int Urol Nephrol       Date:  2015-07-30       Impact factor: 2.370

Review 10.  Strategies for the profiling, characterisation and detailed structural analysis of N-linked oligosaccharides.

Authors:  Tharmala Tharmalingam; Barbara Adamczyk; Margaret A Doherty; Louise Royle; Pauline M Rudd
Journal:  Glycoconj J       Date:  2012-08-26       Impact factor: 2.916
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.